Board approves Dividend
Pursuant to Part A of Schedule III of the SEBI [Listing Obligations and Disclosure Requirements], 2015, we hereby inform that the Board of Directors at their meeting held today approved payment of interim dividend @ of 65% i.e. Rs. 6.5/- per equity share on 3,90,72,089 Equity Shares of Rs. 10/- each of the Company for the Financial Year 20162017.... Outcome of Board Meeting
Pursuant to Part A of Schedule III of the SEBI [Listing Obligations and Disclosure Requirements], 2015, we hereby inform that the Board of Directors at their meeting held today approved payment of interim dividend @ of 65% i.e. Rs. 6.5/- per equity share on 3,90,72,089 Equity Shares of Rs. 10/- each of the Company for the Financial Year 20162017. The Board of Directors has fixed March 14, 2017 as the Record Date to ascertain the list of members... Zydus arm gets USFDA nod to sell anti-viral drug
Zydus Pharmaceuticals US's subsidiary Nesher Pharmaceuticals on Monday informed final approval from the US drug regulator USFDA to market Oseltamivir Phosphate Capsules, USP in the US market.... Zydus gets US FDA nod to start Phase 2 clinical trials of Saroglitazar Magnesium
Healthcare major Zydus Cadila on Thursday announced having received US drug regulator US Food and Drug Administration (USFDA) approval for the group's plans to initiate a Phase-2 clinical trial of... Investor Presentation
Zydus Wellness Ltd has informed BSE regarding Investor Presentation. Zydus gets USFDA nod for drugs treating fungal infections, skin disorder
Company will manufacture Fluconazole tablets at its Baddi facility Fixes Record Date for Interim Dividend
Zydus Wellness Ltd has informed BSE that the Company has fixed March 10, 2017 as the Record Date for the purpose of Payment of Interim Dividend, if declared. Board to consider Interim Dividend
Zydus Wellness Ltd has informed BSE that the Meeting of Board of Directors of the Company will be held on March 01, 2017, to consider, the proposal for declaration of Interim Dividend, if any, for the financial year 2016-2017.Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI [Prohibition of Insider Trading] Regulations, 2015, the Trading Window will remain closed from February 20, 2017 to... Zydus Wellness Q3 profits fall
Cadila Healthcare's subisidiary Zydus Wellness saw flat income for Q3 compared to last year's quarter, and saw profits decline 8.2% to Rs. 25.14 crore. Besides SugarFree, the company also has the brands EverYuth and Nutralite in its stable. Results Press Release for December 31, 2016
Zydus Wellness Ltd has informed BSE about : 1. Result Press Release for the period ended December 31, 2016